title: Clinical experience and acceptability of the etonogestrel subdermal contraceptive implant.
abstract: OBJECTIVE
  To evaluate efficacy, adverse effects, and user continuation rate of an etonogestrel subdermal single-rod contraceptive implant.
  
  
  METHODS
  A total of 417 healthy volunteers of childbearing age were included in this multicenter trial. After implant insertion, the women were followed up during the 3 years of contraceptive action. At each visit, clinical findings, side effects, and bleeding patterns were recorded. Efficacy and continuation rates were analyzed using the Pearl Index and Kaplan-Meier life tables, respectively.
  
  
  RESULTS
  The observation period totaled 958.5 woman-years (27.5 months per woman). The Pearl Index score was 0. Side effects were reported by 44.4% of users, but the proportion had decreased to 16.5% by the end of the study. The continuation rate was 61.4%. The most common reason for early discontinuation (in 21.1% of the participants) was menstrual disturbances.
  
  
  CONCLUSIONS
  Etonogestrel subdermal contraceptive implants demonstrated high efficacy and an acceptable continuation rate. Counseling potential users explicitly about the side effects will optimize patient success with this long-acting contraceptive.
authors.affiliation: Family Planning Division, Office of Reproductive Health, Public Health Unit, Mexican Social Security Institute, Mexico City, Mexico.
authors.forename: J B Otero
authors.initials: JB
authors.lastname: Flores
authors.forename: M Lozano
authors.initials: ML
authors.lastname: Balderas
authors.forename: M Cortés
authors.initials: MC
authors.lastname: Bonilla
authors.forename: L
authors.initials: L
authors.lastname: Vázquez-Estrada
mesh_terms: D000293:Adolescent; D000328:Adult; D003271:Contraceptive Agents, Female / Q000008:administration & dosage* / Q000009:adverse effects; D017135:Desogestrel / Q000008:administration & dosage* / Q000009:adverse effects; D004343:Drug Implants; D005260:Female; D006801:Humans; D008137:Longitudinal Studies; D008597:Menstrual Cycle; D008800:Mexico; D008875:Middle Aged; D017060:Patient Satisfaction; D045167:Progesterone Congeners / Q000008:administration & dosage* / Q000009:adverse effects; D011446:Prospective Studies
chemical_list: D003271:Contraceptive Agents, Female; D004343:Drug Implants; D045167:Progesterone Congeners; C044815:etonogestrel; D017135:Desogestrel